Safety & Tolerability Study of Daily Dosing Rimegepant in Episodic

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03832998` - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Phase 3
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Vestibular Neurectomy	N/A
Completed	`NCT04179474` - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine	Phase 1
Recruiting	`NCT04603976` - Registry for Migraine - Clinical Core	Phase 4
Completed	`NCT03597529` - CHOCOlate MeLatonin for AdolescenT MigrainE	Phase 2
Completed	`NCT04197349` - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman	Phase 1
Enrolling by invitation	`NCT05064371` - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan	Phase 3
Not yet recruiting	`NCT04069572` - Vibratory Stimulation for the Treatment of Chronic Pain	N/A
Not yet recruiting	`NCT04859374` - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach	N/A
Not yet recruiting	`NCT04925414` - Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)	Phase 4
Not yet recruiting	`NCT03083860` - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.	N/A
Completed	`NCT02905227` - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder	Phase 1
Enrolling by invitation	`NCT02532023` - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients	Phase 4
Completed	`NCT02108678` - One-Day Intervention for Depression and Impairment in Migraine Patients	N/A
Completed	`NCT01741246` - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging	N/A
Completed	`NCT01225263` - Statin/Vitamin D & Migraine Study	Phase 2
Completed	`NCT01138150` - Ictal and Interictal Inflammatory Markers in Migraine	Phase 4
Completed	`NCT01080287` - The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras	N/A
Not yet recruiting	`NCT00969995` - Identification of Inflammatory Markers in Migraine Patients	N/A
Completed	`NCT01161667` - Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions	N/A

NCT number	NCT05207865
Study type	Interventional
Source	Biohaven Pharmaceuticals, Inc.
Contact	Elyse Stock, MD
Phone	203-404-0410
Email	[email protected]
Status	Recruiting
Phase	Phase 4
Start date	March 15, 2022
Completion date	September 20, 2023

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms